To obtain a new specific isotetracene compound that has cell adhesion inhibitory action on ICAM-1 participating in T-lymphocyte function manifestation and extravascular infiltration of phlogocytes and is used as an immunosuppressive agent, antiinflammatory agent, antirheumatic agent, etc.
This new isotetracene compound of formula I or II, which has an adhesion inhibitory action on a cell adhesion molecule, ICAM-1, which develops on antigen manifesting cells, autoimmune target cells and vascular endothelial cells, is combined with LFA-1 on T lmpocytes and inflammation- related immune cells, and fully participates in function manifestation of T lymphocytes and extravascular infiltration of phlogocytes, and is useful as an immunosuppressive agent, antiinflammatory agent, antirheumatic agent, etc., is obtained by inoculating Actinomadura rugatobispora TA-0281 (FERM P-15756) on a medium, culturing the inoculated medium at 28°C for 96hr while stirring under condition of aeration, then passing the culture medium through an adsorption resin column, etc., eluting the adsorbate, and partitioning the elute through a column chromatography, etc.
SANADA KAYO
NAKAO TORU
SAITO MASAKO
YAMAMOTO HARUAKI
Next Patent: PRODUCTION OF TAXOL BY CULTURING